Title

Keynote 48: Is it really for everyone?

Authors

Jonathan D. Schoenfeld¹,², Geoffrey Fell², Robert I. Haddad¹,², Lorenzo Trippa²

¹Brigham and Women's Hospital; ²Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA

Corresponding author

Jonathan D. Schoenfeld
Dana Farber Cancer Institute/ Brigham and Women’s Hospital and
Harvard Medical School
450 Brookline Ave.
Boston, MA 02215
P: 617-632-3591
F: 617-632-4247
jonathan_schoenfeld@dfci.harvard.edu

Disclosures

JDS reports research support paid to the institution: Merck, BMS, Regeneron; Consulting / Scientific Advisory Board / Travel fees: Debiopharm, BMS, Nanobiotix, Tilos, AstraZeneca, LEK, Catenion, ACI Clinical, Immunitas; Expert witness fees.
RIH reports consulting for BMS, Merck, AstraZeneca, Pfizer, GSK, Genentech, Celgene and Bayer and Research Support from GSK, Merck, BMS, Pfizer, AstraZeneca, Genentech and Kura.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
Burtness et al. recently published the landmark Keynote-48 study, demonstrating a survival benefit for pembrolizumab monotherapy and pembrolizumab/chemotherapy, compared with cetuximab/chemotherapy, in patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC).1 These data are impactful and practice-changing,2 and have rapidly been adopted in practice, with increasing numbers of HNSCC patients receiving either pembrolizumab monotherapy, or pembrolizumab / chemotherapy, in the first line recurrent / metastatic setting. Pembrolizumab was approved as a single agent for patients whose tumors express PD-L1 (Combined Positive Score [CPS] ≥1), while pembrolizumab / chemotherapy was approved for use in the United States for all patients irrespective of PD-L1 expression.3

In the Keynote-48 study, based on an amended design, overall survival comparisons were made in the PD-L1 CPS >=20, >=1, and total populations; these results defined subsequent regulatory approval. However, these results offer little specific information describing outcomes specifically in patients with low CPS, the suitability of the CPS thresholds chosen, and hypotheses to be tested in future clinical trials.

To address these gaps, we extracted data from Kaplan-Meier curves4 and estimated survival in the CPS<1 population (Figure), which was not reported in the manuscript. This was done by leveraging the fact that the overall survival function is a weighted average of CPS < and >= 1. These data suggest cetuximab/chemotherapy may retain benefit in PD-L1 negative tumors, an observation of potential clinical relevance directly affecting patient care. This approach also illustrates the possibility, in some cases, of estimating group-specific survival distributions for subpopulations of interest even when Kaplan-Meier curves are not provided that can be applied to other trials.
References


2. Ferris RL, Licitra L: PD-1 immunotherapy for recurrent or metastatic HNSCC. Lancet, 2019


Figure (below):

Left: Using an approach outlined in [4], we extracted Kaplan-Meier curves from the pembrolizumab/chemotherapy population and used the survival.function-CPS>=1.0 (red) survival.function-overall.population (black) to estimate survival.function-CPS<1.0 (green, not reported in the original manuscript) using the equation:

weight x survival.function-CPS<1.0 + (1-weight) x survival.function-CPS>=1.0
= survival.function.overall.pop

In this case with weight 39/281.

Right: We compare overall survival following treatment with pembrolizumab/chemotherapy (red) to cetuximab/chemotherapy (black) in the CPS<1 population. Survival functions were estimated as in the left panel.